303
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI)

ORCID Icon, ORCID Icon, , , , , , ORCID Icon, , , , ORCID Icon, , , ORCID Icon, & show all
Pages 881-890 | Published online: 31 Mar 2020

References

  • Perlis RH, Delbello MP, Miyahara S, Wisniewski SR, Sachs GS, Nierenberg AA. Revisiting depressive-prone bipolar disorder: polarity of initial mood episode and disease course among bipolar I systematic treatment enhancement program for bipolar disorder participants. Biol Psychiatry. 2005;58(7):549–553. doi:10.1016/j.biopsych.2005.07.02916197928
  • Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.29536616
  • Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20(2):180–195. doi:10.1093/ijnp/pyw10927941079
  • Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85–116. doi:10.1080/1562297090282320219347775
  • Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015;45(2):299–317. doi:10.1017/S003329171400130525036226
  • Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–359. doi:10.1016/S2215-0366(14)70314-126360999
  • Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand. 2014;130(6):452–469. doi:10.1111/acps.2014.130.issue-625283309
  • Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ. 2012;345:e8508. doi:10.1136/bmj.e850823271744
  • Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53(11):1028–1042. doi:10.1016/S0006-3223(03)00165-312788248
  • Cipriani A, Barbui C, Rendell J, Geddes JR. Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. Acta Psychiatr Scand. 2014;129(5):328–342. doi:10.1111/acps.2014.129.issue-524289821
  • Angst J, Azorin JM, Bowden CL, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry. 2011;68(8):791–798. doi:10.1001/archgenpsychiatry.2011.8721810644
  • Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381(9878):1663–1671. doi:10.1016/S0140-6736(13)60989-723663952
  • Carvalho AF, Takwoingi Y, Sales PMG, et al. Screening for bipolar spectrum disorders: a comprehensive meta-analysis of accuracy studies. J Affect Disord. 2015;172:337–346. doi:10.1016/j.jad.2014.10.02425451435
  • Muneer A. Staging models in bipolar disorder: a systematic review of the literature. Clin Psychopharmacol Neurosci. 2016;14(2):117–130. doi:10.9758/cpn.2016.14.2.11727121423
  • Tohen M, Zarate CA Jr., Hennen J, et al. The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099–2107. doi:10.1176/appi.ajp.160.12.209914638578
  • Haro JM, Reed C, Gonzalez-Pinto A, Novick D, Bertsch J, Vieta E. 2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery. Eur Neuropsychopharmacol. 2011;21(4):287–293. doi:10.1016/j.euroneuro.2010.08.00120956071
  • Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453–473. doi:10.1111/bdi.2009.11.issue-519624385
  • Kogan JN, Otto MW, Bauer MS, et al. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord. 2004;6(6):460–469. doi:10.1111/bdi.2004.6.issue-615541061
  • MacCabe JH, Lambe MP, Cnattingius S, et al. Excellent school performance at age 16 and risk of adult bipolar disorder: national cohort study. Br J Psychiatry. 2010;196(2):109–115. doi:10.1192/bjp.bp.108.06036820118454
  • Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006;163(4):716–723. doi:10.1176/ajp.2006.163.4.71616585449
  • Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2014;16(3):217–229. doi:10.1111/bdi.2014.16.issue-324219657
  • Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537. doi:10.1001/archpsyc.59.6.53012044195
  • Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261–269. doi:10.1001/archpsyc.60.3.26112622659
  • Kanba S, Kato T, Terao T, Yamada K. Guideline for treatment of bipolar disorder by the Japanese society of mood disorders, 2012. Psychiatry Clin Neurosci. 2013;67(5):285–300. doi:10.1111/pcn.1206023773266
  • Sani G, Perugi G, Tondo L. Treatment of bipolar disorder in a lifetime perspective: is lithium still the best choice? Clin Drug Investig. 2017;37(8):713–727.
  • Sani G, Fiorillo A. The use of lithium in mixed states. CNS Spectr. 2019;1–3. doi:10.1017/S1092852919001184
  • Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. doi:10.1177/026988111663654526979387
  • Li DJ, Lin CH, Chen FC. Factors affecting time to remission for inpatients with bipolar mania - A naturalistic Taiwanese study. J Affect Disord. 2018;232:73–78. doi:10.1016/j.jad.2018.02.03229477587
  • Bukh JD, Andersen PK, Kessing LV. Rates and predictors of remission, recurrence and conversion to bipolar disorder after the first lifetime episode of depression–a prospective 5-year follow-up study. Psychol Med. 2016;46(6):1151–1161. doi:10.1017/S003329171500267626743873
  • Farren CK, Hill KP, Weiss RD. Bipolar disorder and alcohol use disorder: a review. Curr Psychiatry Rep. 2012;14(6):659–666. doi:10.1007/s11920-012-0320-922983943
  • Ferrari AJ, Baxter AJ, Whiteford HA. A systematic review of the global distribution and availability of prevalence data for bipolar disorder. J Affect Disord. 2011;134(1–3):1–13. doi:10.1016/j.jad.2010.11.00721131055
  • Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand. 2000;101(6):444–451. doi:10.1034/j.1600-0447.2000.101006444.x10868467
  • Dawson EL, Shear PK, Howe SR, et al. Impulsivity predicts time to reach euthymia in adults with bipolar disorder. Bipolar Disord. 2014;16(8):846–856. doi:10.1111/bdi.2014.16.issue-825039396
  • Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130(1–2):171–179. doi:10.1016/j.jad.2010.10.02621071096
  • Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry. 2011;72(9):1236–1241. doi:10.4088/JCP.09m05874yel21457677
  • Perugi G, Medda P, Barbuti M, Novi M, Tripodi B. The role of electroconvulsive therapy in the treatment of severe bipolar mixed state. Psychiatr Clin North Am. 2020;43(1):187–197. doi:10.1016/j.psc.2019.10.01032008684
  • Bersani FS, Girardi N, Sanna L, et al. Deep transcranial magnetic stimulation for treatment-resistant bipolar depression: a case report of acute and maintenance efficacy. Neurocase. 2013;19(5):451–457. doi:10.1080/13554794.2012.69042922827578